Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 10,845 matching trials from the live ClinicalTrials.gov search.
Filters: Columbus, Ohio Clear all
Active, not recruiting Not applicable Interventional

Mobile Health for Adherence in Breast Cancer Patients

NCT06112613
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Health Promotion and Education, Health Telemonitoring, Patient Navigation, Survey Administration, Text Message-Based Navigation Intervention
Other · Procedure · Behavioral
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
499
States / cities
Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 338 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

NCT00056160
View directory record Official record
Conditions
Multiple Myeloma
Interventions
CC-5013, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
44
States / cities
Hoover, Alabama • Duarte, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 31, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional

HyaloFAST Trial for Repair of Articular Cartilage in the Knee

NCT02659215
View directory record Official record
Conditions
Defect of Articular Cartilage
Interventions
Hyalofast, Microfracture
Device · Procedure
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
18
States / cities
Tempe, Arizona • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NCT02360215
View directory record Official record
Conditions
Cognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm
Interventions
Whole brain radiation therapy with hippocampal avoidance, Memantine, Whole brain radiation therapy
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
212
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Completed No phase listed Observational

Remote Assessment of Cognition, Insulin Resistance and Omega-3 Fatty Acid Biomarkers in Breast Cancer Survivors

NCT05048108
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT04052997
View directory record Official record
Conditions
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Camidanlumab Tesirine
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
16 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
24
States / cities
Scottsdale, Arizona • Duarte, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 31, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 31, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

NCT05898620
View directory record Official record
Conditions
Rett Syndrome
Interventions
NGN-401
Genetic
Lead sponsor
Neurogene Inc.
Industry
Eligibility
3 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Oakland, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers

NCT00829582
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ETI-204, "Anthim", placebo
Drug · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

NCT03015896
View directory record Official record
Conditions
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab
Other · Drug · Biological
Lead sponsor
David Bond, MD
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996
View directory record Official record
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma
Interventions
Sonrotoclax, Zanubrutinib, Placebo
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

NCT02042443
View directory record Official record
Conditions
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
295
States / cities
Anchorage, Alaska • Anaheim, California • Auburn, California + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

NCT02988115
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction
Interventions
bempedoic acid, placebo
Drug · Other
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Gilbert, Arizona • Anaheim, California • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 31, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

NCT05686317
View directory record Official record
Conditions
Heart Failure
Interventions
Edwards APTURE transcatheter shunt system, Sham procedure
Device · Diagnostic Test
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

NCT00333840
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
62
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)

NCT00014989
View directory record Official record
Conditions
Cerebral Palsy, Intraventricular Hemorrhage, Periventricular Leukomalacia, Pulmonary Edema, Abruptio Placentae
Interventions
magnesium sulfate
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
2,136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
17
States / cities
Birmingham, Alabama • Miami, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Open-label Extension to Protocol 1042-0600

NCT00512317
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 4 Interventional

Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis

NCT04891640
View directory record Official record
Conditions
Juvenile Spondyloarthritis
Interventions
Standard TNFi Therapy, TNFi fixed longer dosing intervals, Stop TNFi treatment
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial

NCT06216574
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Internet-based Intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
236
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Antioch, California + 199 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

Improving Arm Mobility and Use After Stroke

NCT00057018
View directory record Official record
Conditions
Cerebrovascular Accident
Interventions
Constraint-induced movement therapy
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 80 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 31, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Capivasertib, Paclitaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
22
States / cities
Whittier, California • Fort Myers, Florida • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 31, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant

NCT02610296
View directory record Official record
Conditions
Delayed Graft Function
Interventions
QPI-1002, Placebo
Drug · Other
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 31, 2026, 5:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation

NCT07256717
View directory record Official record
Conditions
Physical Fitness
Interventions
Balanced Progressive Intensity Training (BPIT) 5-Line Method
Behavioral
Lead sponsor
MMSx Authority Institute for Movement Mechanics & Biomechanics Research Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
369 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Columbus, Ohio • Powell, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 31, 2026, 5:26 PM EDT